CTLT - Catalent, Inc.

NYSE - NYSE Delayed Price. Currency in USD
53.24
+2.96 (+5.89%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close50.28
Open50.70
Bid53.27 x 1300
Ask53.29 x 800
Day's Range50.70 - 54.10
52 Week Range29.23 - 54.10
Volume1,916,544
Avg. Volume838,950
Market Cap7.758B
Beta (3Y Monthly)1.83
PE Ratio (TTM)50.90
EPS (TTM)1.05
Earnings DateAug 26, 2019 - Aug 30, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est50.40
Trade prices are not sourced from all markets
  • Did Hedge Funds Drop The Ball On Catalent Inc (CTLT) ?
    Insider Monkey14 hours ago

    Did Hedge Funds Drop The Ball On Catalent Inc (CTLT) ?

    We can judge whether Catalent Inc (NYSE:CTLT) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There's no better way to get these firms' immense resources and analytical capabilities working for us than to follow their lead into their best ideas. […]

  • Catalent (CTLT) Upgraded to Buy: What Does It Mean for the Stock?
    Zacks5 days ago

    Catalent (CTLT) Upgraded to Buy: What Does It Mean for the Stock?

    Catalent (CTLT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).

  • Business Wire5 days ago

    Catalent to Purchase Bristol-Myers Squibb Manufacturing Facility in Anagni, Italy

    Bristol-Myers Squibb Company (BMY) and Catalent, Inc. (CTLT), today announced that Catalent has agreed to purchase Bristol-Myers Squibb’s oral solid, biologics, and sterile product manufacturing and packaging facility in Anagni, Italy. Catalent is the leading global provider of advanced delivery technologies, development and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products.

  • Markit14 days ago

    See what the IHS Markit Score report has to say about Catalent Inc.

    Catalent Inc NYSE:CTLTView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for CTLT with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding CTLT totaled $49 million. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Business Wire25 days ago

    Catalent, Inc. to Present at the Jefferies Healthcare Conference

    Catalent, Inc. , the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that Wetteny Joseph, Senior Vice President & Chief Financial Officer, will present at the Jefferies Healthcare Conference at 3:00 p.m.

  • Catalent Acquires Gene Therapy Leader Paragon Bioservices
    Zackslast month

    Catalent Acquires Gene Therapy Leader Paragon Bioservices

    Catalent (CTLT) acquires gene therapy leader Paragon Bioservices for $1.2 billion.

  • Business Wirelast month

    Catalent Completes Acquisition of Gene Therapy Leader Paragon Bioservices, Inc. for $1.2 Billion

    Catalent, Inc. (CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has completed the $1.2 billion acquisition of Paragon Bioservices, Inc., a leading viral vector development and manufacturing partner for gene therapies. With the addition of Paragon’s specialized expertise in adeno-associated virus (AAV) vectors, the most commonly used vector to deliver DNA to cells, Catalent is positioned to capitalize on strong industry tailwinds in the potentially $40 billion addressable market for gene therapies.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of CTLT earnings conference call or presentation 7-May-19 12:15pm GMT

    Q3 2019 Catalent Inc Earnings Call

  • Moody's2 months ago

    Catalent Pharma Solutions, Inc. -- Moody's downgrades Catalent's senior secured rating to Ba3, affirms B1 CFR rating; the outlook remains stable

    Moody's Investors Service ("Moody's") downgraded Catalent Pharma Solutions, Inc. ("Catalent")'s senior secured credit ratings to Ba3 from Ba2. At the same time, Moody's affirmed Catalent's B1 Corporate Family Rating (CFR), the B1-PD Probability of Default Rating, and the B3 senior unsecured rating.

  • Catalent Inc (CTLT) Q3 2019 Earnings Call Transcript
    Motley Fool2 months ago

    Catalent Inc (CTLT) Q3 2019 Earnings Call Transcript

    CTLT earnings call for the period ending March 31, 2019.

  • Catalent (CTLT) Surpasses Q3 Earnings Estimates
    Zacks2 months ago

    Catalent (CTLT) Surpasses Q3 Earnings Estimates

    Catalent (CTLT) delivered earnings and revenue surprises of 8.89% and -4.14%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Catalent: Fiscal 3Q Earnings Snapshot

    The Somerset, New Jersey-based company said it had net income of 22 cents per share. Earnings, adjusted for one-time gains and costs, were 49 cents per share. The results topped Wall Street expectations. ...

  • Business Wire2 months ago

    Catalent, Inc. Reports Third Quarter Fiscal 2019 Results

    SOMERSET, N.J.-- -- Q3'19 revenue of $617.5 million decreased 2% as-reported, but increased 2% in constant currency, from Q3'18, while Q3'19 YTD revenue of $1,792.3 million increased 1% as-reported, or 3% in constant currency, from the prior-year period. Double-digit organic segment EBITDA growth within Biologics and Specialty Drug Delivery, Oral Drug Delivery and Clinical Supply Services segments; ...

  • Catalent (CTLT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
    Zacks2 months ago

    Catalent (CTLT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

    Catalent (CTLT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Moody's2 months ago

    Catalent Pharma Solutions, Inc. -- Moody's announces completion of a periodic review of ratings of Catalent Pharma Solutions, Inc.

    Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Catalent Pharma Solutions, Inc. New York, April 17, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Catalent Pharma Solutions, Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.

  • Moody's2 months ago

    Catalent Pharma Solutions, Inc. -- Moody's: Catalent's acquisition of Paragon will increase leverage, a credit negative

    New York, April 17, 2019 -- Moody's Investors Service ("Moody's") commented that Catalent Pharma Solutions, Inc.'s proposed acquisition of Paragon Bioservices for $1.2 billion in cash will increase the company's financial leverage, a credit negative. For additional information please refer to Moody's Issuer Comment on Catalent Pharma Solutions available on www.moodys.com. Headquartered in Somerset, New Jersey, Catalent Pharma Solutions, Inc. is a leading provider of development solutions and advanced delivery technologies for drugs, biologics and consumer health products.

  • Reuters2 months ago

    Catalent seeks slice of gene therapy market with Paragon buy

    Paragon, backed by private-equity firms Camden Partners and NewSpring Capital, focuses on developing and making complex biopharmaceuticals for its clients and is expected to bring in more than $200 million in revenue this year, Catalent said. "Paragon's unparalleled expertise in the rapidly growing market of gene therapy manufacturing will be a transformative addition to our business that we believe will accelerate our long-term growth," Catalent Chief Executive Officer John Chiminski said in a statement. Most emerging drug companies lack the resources to manufacture drugs and rely on contract organizations such as Catalent and Paragon to make the drugs using their technology.

  • TheStreet.com2 months ago

    Catalent to Buy Paragon Bioservices for $1.2 Billion

    announced Monday that it has agreed to buy closely held Paragon Bioservices for $1.2 billion in cash, the latest deal in the burgeoning gene-therapy drug area. The Wall Street Journal had reported earlier Monday that Catalent would announce the all-cash deal for Paragon, paving the way for its entry into the burgeoning gene-therapy drug market. Catalent, which develops and manufactures drugs for pharmaceutical companies, had about $2.5 billion in sales last year.

  • Benzinga2 months ago

    Catalent Agrees To Buy Gene Therapy-Focused CDMO Paragon Services For $1.2B

    Gene therapy deal news continues to trickle in after Catalent Inc (NYSE: CTLT) announced an agreement to buy another gene and cell therapy CDMO. Catalent, which provides technologies and integrated solutions for biologic and biosimilar development, said it has entered into a definitive agreement to buy Paragon Services, a viral vector development and manufacturing partner for gene therapies, for $1.2 billion in cash. Catalent expects to fund the transaction partly from its existing credit facilities and partly from an issuance of preferred equity.

  • CNBC2 months ago

    Stocks making the biggest moves premarket: Goldman Sachs, CVS, Best Buy, Facebook & more

    Check out the companies making headlines before the bell: Goldman Sachs GS — The investment bank reported quarterly profit of $5.71 per share , beating the consensus estimate of $4.89. Revenue fell short of forecasts, however.

  • MarketWatch2 months ago

    Catalent to acquire Paragon Bioservices for $1.2 billion in cash

    Catalent Inc. said Monday it has agreed to acquire Paragon Bioservices Inc. for $1.2 billion in cash. Calent, a provider of delivery technologies for drugs, biologics and consumer health products, said it expects the deal to close in the second quarter. Privately held Paragon is a viral vector development and manufacturing partner for gene therapies. "Paragon brings specialized expertise in adeno-associated virus (AAV) vectors, the most commonly used delivery system for gene therapy, as well as unique capabilities in GMP plasmids and lentivirus vectors," Catalent said in a statement. Paragon is expected to generate more than $200 million in revenue in 2019 with nearly 90% of that sum already in signed contracts. The deal is expected to boost Catalent's adjusted net income per share in the second full fiscal year after closing. Catalent will finance the deal with the proceeds of a $650 million term loan and by issuing $650 million of convertible preferred stock to funds tied to Leonard Green and Partners LP. Shares were not yet active premarket, but have fallen 2.4% in the last 12 months, while the S&P 500 has gained 9.5%.

  • Reuters2 months ago

    Catalent to buy Paragon Bioservices for $1.2 bln

    Catalent Inc said on Monday it would buy privately held gene therapy-focused Paragon Bioservices Inc in an all-cash deal for $1.2 billion. Paragon, backed by private-equity firms Camden Partners and NewSpring ...